



Thank you for selecting our infusion services team to care for your patient. If you are not a PeaceHealth provider, all information listed below is required before we can process orders and schedule your patient for treatment.

Part A- Patient scheduling and contact information:

Patient Name (Last, First): _____ Date of Birth: _____

Patient Contact Information and Phone Number (s): _____

Ordering Provider Name (Print): _____

Provider Clinic or Service Address: _____

Clinic or Service Phone Number: _____ Clinic or Service Fax Number: _____

Diagnosis (include ICD 10 codes): _____

Medication and Service Requested- list J-Code/ CPT code if known: _____

Date Service is Requested to Begin: _____ Date Service is Expected to End: _____

Order will expire 1 year from date of provider signature unless "date service is expected to end" is earlier.

Part B- Insurance and Prior Authorization. Any non-PeaceHealth provider must obtain prior authorization prior to service. Attach a copy of authorization documentation received from insurance payer when submitting orders.

Insurance (Payer) Company: _____

Prior Authorization Number and Conditions: _____

Prior Authorization Expiration Date: _____

Insurance (Payer) Contact Phone Number: _____

Part C- Elements needed to guide medication therapy are included with request for service:

- All orders and instruction (please use the PeaceHealth approved ordering form) are complete and include provider signature AND printed name at the bottom of each order page. Check the boxes of ALL orders you would like to activate.
- For blood products, PeaceHealth Blood and Transfusion Consent form is signed and dated by the provider and the patient.

If information is located outside of PeaceHealth's electronic medical record system attach the following:

- A list of current medications reconciled by patient provider is available and includes a list of known allergies.
- Recent progress notes from ordering provider.
- A copy of relevant laboratory results and other appropriate supporting documentation.

IMPORTANT MESSAGE TO PROVIDERS: To reduce delays in treatment and phone calls to your office you may participate in the PHMC formulary process by signing this document. A clinical pharmacist will adjust orders according to PHMC approved policies and procedures.

I agree to utilize PHMC policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PHMC. This agreement will be issued for the duration of active orders contained within this treatment plan.

PROVIDER SIGNATURE: _____ **DATE:** _____ **TIME:** _____

FAX completed service request and completed orders to: PHMC OP Infusion and Nursing Services 541-902-1649



Romosozumab (Evenity) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
For Admission to Service	<p>Provider Instruction- Review the information below and address requirements for admission to service:</p> <ol style="list-style-type: none"> 1. Romosozumab administration is restricted to the following: <ol style="list-style-type: none"> a. Diagnosis of osteoporosis in a postmenopausal female considered to be a high fracture risk. <ol style="list-style-type: none"> i. Bone mass T score of less than 3, OR ii. Bone mass T score of less than 2.5 with fracture history. b. May be considered for use as an alternative agent if no other first line agent is tolerated or effective. (i.e., patient has failed denosumab, ibandronate, zoledronic acid) c. Continuation of therapy 2. Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Do not initiate treatment in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, romosozumab should be discontinued. 3. CMP is required prior to patient beginning treatment (see order below). 4. Correct hypocalcemia and vitamin D deficiency (e.g., to a 25-hydroxyvitamin D level ≥ 20 ng/mL [≥ 50 nmol/L]) prior to initiating therapy and ensure adequate calcium and vitamin D intake during therapy. <ol style="list-style-type: none"> a. Although the optimal intake (diet plus supplement) has not been clearly established in osteoporosis, 1000 – 1200 mg of calcium (total of diet and supplement) and 600 – 800 units of vitamin D daily are generally suggested. 5. Remind patient of importance of good dental hygiene and ensure patient has had a satisfactory dental exam prior to start of therapy. (Risk for osteonecrosis of jaw) 6. Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. 7. Review medication information and provide patient with a written copy the FDA-approved Medication Guide for Romosozumab.
Supportive Care	<p><input checked="" type="checkbox"/> Romosozumab 210 mg subcutaneously once a month for 12 doses only.</p>
Nursing Orders	<p><input checked="" type="checkbox"/> Nursing communication – Remind patient of good dental hygiene and to avoid dental procedures other than cleaning.</p> <p><input checked="" type="checkbox"/> Draw CMP at baseline, wait for lab result. If corrected calcium is less than 8.5, hold treatment and contact provider. Draw CMP at month 6 and month 12 of treatment. Do not wait for lab result to proceed with treatment. If calcium is less than 8.5, contact provider for instructions.</p>
Labs	<p><input checked="" type="checkbox"/> CMP once prior to initial treatment.</p> <p><input checked="" type="checkbox"/> CMP at month 6 and month 12 of treatment.</p> <p><input checked="" type="checkbox"/> Provider approves to release and draw labs 2 days pre and post the planned treatment dates.</p>
Emergency Medications	<p>If patient has symptoms of anaphylaxis (wheezing, dyspnea, hypotension, angioedema, chest pain, or tongue swelling), discontinue infusion and initiate standard emergency response procedures.</p> <p><input checked="" type="checkbox"/> Standard Emergency Medications:</p>

Practitioner Signature: _____ **Date of Order:** _____ **Time:** _____

Final page of orders must include signature of the ordering practitioner, date, and time.

Patient Identification Label



**Romozumab (Evenity)
Outpatient Infusion Therapy Plan**

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
	<p><input checked="" type="checkbox"/> DiphenhydrAMINE (Benadryl) injection 25-50 mg IM once as needed for mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>= 20 points in SBP), nausea, urticaria, chills, pruritic).</p> <ul style="list-style-type: none"> • Administer 50 mg IM if patient has NOT had diphenhydramine within 2 hours of reaction • Administer 25 mg IM if patient has had diphenhydramine within 2 hours of reaction, if reaction doesn't resolve in 3 minutes may repeat 25 mg IM dose for a total of 50 mg and contact provider. <p><input checked="" type="checkbox"/> Albuterol 90 mcg/actuation inhaler 2 puffs once as needed for wheezing, shortness of breath associated with infusion reaction and contact provider. Administer with a spacer if available.</p> <p><input checked="" type="checkbox"/> MethylPREDNISolone (Solu-Medrol) injection 125 mg IM once as needed for shortness of breath for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>= 20 points in SBP), nausea, urticaria, chills, pruritic) that worsen or persist 5 minutes after administration of diphenhydramine (Benadryl) and contact provider. Do not inject into deltoid.</p> <p><input checked="" type="checkbox"/> EPINEPHrine (Adrenalin) injection 0.5 mg IM once as needed for severe drug reaction (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort plus blood pressure changes (>= 40 points in SBP), shortness of breath with wheezing and O2 Sat less than 90% and contact provider.</p>
Referral	<input checked="" type="checkbox"/> Ambulatory referral to OP Infusion Services
PHMC Outpatient Infusion Contact Information	<p>PROVIDER – PLEASE SIGN, DATE AND TIME ORDERS AND RETURN TO:</p> <p>PeaceHealth Peace Harbor Medical Center Outpatient Infusion Services Department 400 Ninth Street, Florence, OR 97439 Contact Phone: 541-902-6019 and FAX 541-902-1649</p>
Authorization by Verbal or Telephone Order	<p>Person giving verbal or telephone order: _____</p> <p>Person receiving verbal or telephone order: _____</p> <p><input type="checkbox"/> Check to indicate verbal or telephone orders have been read back to confirm accuracy</p>

Practitioner Signature: _____ **Date of Order:** _____ **Time:** _____
 Final page of orders must include signature of the ordering practitioner, date, and time.